Rashmi Chugh
Professor of Internal Medicine and Service Chief
Internal Medicine
Internal Medicine - Hematology/Oncology
1500 East Medical Center Drive, C407 MIB
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Rashmi Chugh
Clinical Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors.
      Manji GA, Stanton LJ, Ge L, Sta Ana S, Chrisinger J, Titus S, Labadie BW, May MS, Lyu Y, Sender N, Tan A-C, Monga V, Chugh R, Hirbe AC, Lee SM, Van Tine BA, Schwartz GK. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 11565 - 11565. DOI:10.1200/jco.2024.42.16_suppl.11565
    • Journal Article
      SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).
      Grohar PJ, Ballman KV, Heise R, Mascarenhas L, Glod J, Wedekind MFF, Gedminas JM, DuBois SG, Maki RG, Crompton BD, Figg WD, Bagatell R, Laetsch TW, Diamond M, Navid F, Roberts RD, Widemann BC, Reinke DK, Chugh R. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 11508 - 11508. DOI:10.1200/jco.2024.42.16_suppl.11508
    • Journal Article
      Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.
      Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. J Clin Oncol, 2024 May 1; 42 (13): 1472 - 1476. DOI:10.1200/JCO.23.02266
      PMID: 38427923
    • Journal Article
      Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
      Dumbrava EE, Iwamoto FM, Agulnik M, Milhem M, Tolcher AW, Chugh R, Demeure MJ, Mita A, Demel K, Diamond M, Mirakhur B, Wilson L, Oganesian A, Chan D, Keer HN, Taylor J, Sims MJ, Biondo A, Jueliger S, Spira A. Cancer Research, 2024 Apr 5; 84 (7_Supplement): ct066 - ct066. DOI:10.1158/1538-7445.am2024-ct066
    • Journal Article
      Abstract CT158: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
      Calero MV, Agulnik M, Mita M, Mita A, Federman N, Rasco D, Spigel D, Luo J, Hanna G, Cote G, Salkeni MA, Chugh R, Ammakkanavar NR, Shah SA, Rao A, Sankhala KK, Cutler RE, Hood T, Carvajal L, MacKenzie C, Lin C, DiMartino J, Olek EA, Van Tine B. Cancer Research, 2024 Apr 5; 84 (7_Supplement): ct158 - ct158. DOI:10.1158/1538-7445.am2024-ct158
    • Presentation
      Biomarkers in Sarcoma
      Chugh R, Mostafa N. 2024 Mar 9;
    • Journal Article
      57MO Impact of nirogacestat (niro) on patient-reported outcomes (PROs) in adults with desmoid tumor with a best overall response (BOR) of stable disease (SD): Post hoc analysis from the DeFi study
      Stacchiotti S, Chawla SP, Chugh R, D'Amato G, Gounder M, Ratan R, van der Graaf WTA, Amoruccio V, Bell T, Cho S, Schöffski P. ESMO Open, 2024 Mar; 9: 102447 DOI:10.1016/j.esmoop.2024.102447
    • Journal Article
      Body image disturbances in adolescent and young adult cancer patients confronting infertility risk and fertility preservation decisions.
      Wytiaz V, Jackson Levin N, Tan CY, Stelmak D, Iannarino N, Zhang A, Ellman E, Herrel L, Moravek M, Walling E, Chugh R, Zebrack B. J Psychosoc Oncol, 2024 42 (2): 208 - 222. DOI:10.1080/07347332.2023.2235607
      PMID: 37452662